Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohort PSOBIOTEQ

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 36; no. 11; pp. 2101 - 2112
• Main Authors: Curmin, R., Guillo, S., De Rycke, Y., Bachelez, H., Beylot‐Barry, M., Beneton, N., Chosidow, O., Dupuy, A., Joly, P., Jullien, D., Richard, M.A., Viguier, M., Sbidian, E., Paul, C., Mahé, E., Tubach, F.
• Format: Journal Article
• Language: English
• Published: England Wiley 01.11.2022
• Subjects: Adalimumab - therapeutic use; Adult; Biological Products - therapeutic use; Dermatology; Etanercept - therapeutic use; Human health and pathology; Humans; Immunology; Immunotherapy; Interleukin-17; Life Sciences; Psoriasis - drug therapy; Santé publique et épidémiologie; Severity of Illness Index; Tumor Necrosis Factor-alpha; Ustekinumab - therapeutic use
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.18409

Background Biologics are the cornerstone of treatment of patients with moderate‐to‐severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. Objectives The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents. Methods We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate‐to‐severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra‐class – i.e. within the same therapeutic class ‐ vs. inter‐class) in patients switching from a TNF‐alpha inhibitor using multivariate logistic regression. Results A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF‐alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL‐17 inhibitor. Patients switching from a first‐line TNF‐alpha inhibitor before 2016 were more likely to switch to another TNF‐alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF‐alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab. Conclusion This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL‐17 inhibitors.